TriangleSunitinib (NCT05366816)
Sunitinib trial for Gastrointestinal Stromal Tumors (NCT05366816). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic GIST after imatinib, with a secondary KIT exon 13 or 17 mutation. Prior sunitinib or regorafenib is excluded; no more than two prior kinase-inhibitor regimens are allowed.
The idea: use mutation testing to select growth-signal blockers. Exon 13 starts oral sunitinib; exon 17 starts oral regorafenib. Switching drugs is optional after progression. Researchers measure tumor response.
This phase 2 study plans 48 patients. Jonathan Trent leads at the University of Miami, the sole recruiting US site. Treatment lasts up to twelve months.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.